Guidelines for screening and management of late and long-term consequences of myeloma and its treatment-Reference-Cited by-同舟云学术

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment

Published:2017-01-20 Issue:6 Volume:176 Page:888-907
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Snowden John A.¹²,Greenfield Diana M.²³,Bird Jennifer M.⁴,Boland Elaine⁵,Bowcock Stella⁶,Fisher Abigail⁷,Low Eric⁸,Morris Monica⁸,Yong Kwee⁷,Pratt Guy⁹,

Affiliation:

1. Department of Haematology; Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield UK

2. Department of Oncology and Metabolism; University of Sheffield; Sheffield UK

3. Department of Oncology; Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield UK

4. University Hospitals Bristol NHS Foundation Trust; Bristol UK

5. Palliative Medicine; Queen's Centre for Oncology and Haematology; Hull and East Yorkshire Hospitals NHS Trust; Hull UK

6. King's College Hospital NHS Foundation Trust; London UK

7. University College London; London UK

8. Myeloma UK; Edinburgh UK

9. University Hospitals Birmingham NHS Foundation Trust; Birmingham UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14514/fullpdf

Reference150 articles.

1. Holistic assessment of supportive and palliative care needs; the evidence for routine systematic questioning.;Ahmed;BMJ Supportive & Palliative Care,2015

2. Palliative medicine and modern cancer care;Ahmedzai;Seminars in Oncology,2000

3. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma;Attal;New England Journal of Medicine,2012

4. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party;Augustson;Journal of Clinical Oncology,2005

5. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989;Barlogie;Blood,2008

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27

2. Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group;Frontiers in Health Services;2024-04-24

3. The Role of Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Multiple Myeloma: Is It Time to Rethink the Paradigm in the Era of Targeted Therapy?;Hemato;2024-04-09

4. Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma;Cancers;2024-03-15

5. Case Report on a Multidisciplinary Approach to Address Malnutrition and Improve a Patient’s Fitness for Treatment;Nutrition and Cancer;2024-02-29